- Onco-Innovations (CBOE CA:ONCO) stated that the co-founders of its wholly-owned subsidiary, Inka Health Corp., have authored an intriguing new study
- The study addresses a critical challenge in oncology research: how to ensure that clinical trial results are relevant and applicable to the diverse patient populations encountered in everyday clinical practice across different countries and healthcare systems
- Using advanced modeling techniques, the study demonstrated that trial outcomes could be translated to real-world settings with pinpoint accuracy—within less than one percent error over a 30-month period
- Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23
This content has been prepared in collaboration with Onco-Innovations Ltd., a third-party issuer, and is intended for informational purposes only.
Onco-Innovations (CBOE CA:ONCO) stated that the co-founders of its wholly-owned subsidiary, Inka Health Corp., have authored an intriguing new study titled Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations: A Case Study using Lung-MAP S1400I, published in medRxiv in June 2025.
The study addresses a critical challenge in oncology research: how to ensure that clinical trial results are relevant and applicable to the diverse patient populations encountered in everyday clinical practice across different countries and healthcare systems. Using advanced modeling techniques, the study demonstrated that trial outcomes could be translated to real-world settings with pinpoint accuracy—within less than one percent error over a 30-month period.
Implications for global drug development
The findings have significant implications for the future of clinical trial design and drug development. By simulating patient outcomes in advance, researchers can optimize trial parameters and better define target populations, reducing risk and accelerating development timelines. These methodologies are foundational to SynoGraph, Inka Health’s next-generation causal AI platform, which aims to revolutionize drug development through globally applicable, real-world analytics.
Study highlights
The research focused on the Lung-MAP S1400I trial, a leading randomized study for advanced non-small cell lung cancer (NSCLC). It evaluated whether trial results could accurately predict outcomes for real-world patients in the U.S., Germany, and France—many of whom would not have qualified for the original trial due to age, comorbidities, or other factors.
Key findings include:
- Enhanced predictive accuracy: By incorporating external clinical knowledge, the model achieved an average discrepancy of just 0.27 months (8.2 days) between predicted and actual survival outcomes.
- Broader applicability: The approach significantly improved the alignment of trial results with real-world outcomes, offering a scalable solution for global oncology research.
- Regulatory relevance: The study supports growing demands from regulators, payers, and clinicians for evidence that reflects real-world patient experiences.
Leadership insights
Among the study’s co-authors is Dr. Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. A globally recognized leader in oncology, Dr. Subbiah has led over 100 early-phase clinical trials and contributed to multiple FDA and EMA approvals, including tissue-agnostic therapies targeting BRAF and RET genetic alterations. He has authored more than 400 peer-reviewed publications in top-tier journals such as The New England Journal of Medicine, Nature Medicine, and JAMA Oncology.
“The ability to model outcomes for patient groups who wouldn’t typically be included in clinical trials is not just a technical achievement-it’s a clinical and strategic one,” he said in a news release. “It opens the door to faster trial design, smarter expansion decisions, and better evidence for patients who are often overlooked. These kinds of tools will be essential as we push toward more globally inclusive and data-driven drug development.”
Onco-Innovations Ltd. studies cancer research and treatment, specializing in oncology.
Onco-Innovations (CBOE CA:ONCO) last traded at C$2.23.
Join the discussion: Find out what everybody’s saying about this stock on the Onco-Innovations Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein.
